Prostate biopsy and multiparametric MRI

Guidelines developed in partnership with

Cite this guideline

Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Sydney: Cancer Council Australia. [Version URL: http://wiki.cancer.org.au/australiawiki/index.php?oldid=122832, cited 2023 Mar 30]. Available from: https://wiki.cancer.org.au/australia/Guidelines:PSA_Testing/Prostate_biopsy_and_multiparametric_MRI.

This resource has been developed, reviewed or revised more than five years ago. It may no longer reflect current evidence or best practice.

Published: 2015

National Health and Medical Research Council

These guidelines (recommendations) in the web-version of this guideline were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 November 2015 under section 14A of the National Health and Medical Research Council Act 1992 In approving the guidelines (recommendations), NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years. NHMRC is satisfied that the guidelines (recommendations) are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.

This publication reflects the views of the authors and not necessarily the views of the Australian Government.

When prostate biopsy is indicated for men with suspected prostate cancer, the optimal protocol for investigation involves determining:

• criteria for an adequate prostate biopsy
• which further investigations, if any, are indicated if prostate cancer is not found in an adequate initial biopsy.

The use of multiparametric magnetic resonance imaging (MRI) in men with elevated prostate-specific antigen (PSA) levels who have not yet undergone an initial biopsy is beyond the scope of this guideline.ⁱ

Footnote

ⁱ This chapter focuses on the use of multiparametric MRI after a negative prostate biopsy, not on its use for the primary investigation of a positive PSA test, because this is not routine clinical practice.